AKT1 and prostate cancer: In addition, our recent studies have shown that atelocollagen-mediated, systemic administration of siRNAs specific for the androgen receptor and three Akt isoforms resulted in significant growth inhibition of human prostate cancer in nude mice, without severe side effects such as lung, liver, or renal damage [24, 25].